• AMPK–SQSTM1 Feedback Under Metabolic Stress

  2026-10-05

  The 2024 Autophagy study identifies a double-positive feedback loop in which AMPK and SQSTM1/p62 reinforce one another during metabolic stress, jointly activating AMPK and NFE2L2/NRF2 antioxidant programs. The work links lysosomal pH, TFEB/TFE3, TAK1, lysosomal calcium signaling, KEAP1 turnover, and AXIN–STK11–AMPK complex formation, while remaining primarily a preclinical, cell-based framework for understanding tumor adaptation.

• Carbapenemase Gene Dynamics in Enterobacter cloacae

  2026-10-05

  A 2025 multicenter study examined carbapenemase-encoding genes, their genomic location, mobility, and strain relatedness in 54 carbapenem-resistant Enterobacter cloacae isolates from eight teaching hospitals in Guangdong. The results point to plasmid-associated blaNDM-1, multidrug resistance, and potential horizontal dissemination, while also showing why isolate surveillance should not be interpreted as direct evidence of hospital transmission or treatment efficacy.

• Hypoxia and Immunometabolism in Tumors

  2026-10-04

  Wu et al. present a review-level synthesis in Cancer Letters that connects tumor hypoxia with nutrient competition, immune-cell metabolic dysfunction, and formation of an immunosuppressive tumor microenvironment. Its main implication is that glucose metabolism research and therapeutic reasoning should examine oxygen availability, metabolic state, and immune function as an interconnected system rather than as isolated variables.

• Annexin V-APC/7-AAD in Translational Cell Death Research

  2026-10-03

  A thought-leadership analysis of how dual-parameter cell-death profiling can strengthen translational interpretation of PAD4 and NET-focused cancer research.

• Meropenem Workflows for Resistance Research

  2026-10-02

  Build reproducible Meropenem MIC, time-kill, resistance-selection, and delivery assays with practical controls for β-lactam stability. This guide translates PK/PD lessons from ceftolozane/tazobactam research into research-use-only workflows for Gram-negative and Gram-positive models.

• E. coli Uracil-DNA Glycosylase (UDG) Guide

  2026-10-01

  K1107 is a recombinant E. coli Uracil-DNA Glycosylase for excising uracil from single- and double-stranded DNA, supporting PCR product contamination elimination and related DNA repair workflows. It is not intended for RNA, oligonucleotides shorter than six bases, or diagnostic and medical applications.

• Tropifexor (LJN452) in Reliable Cell Assays

  2026-10-01

  Learn how Tropifexor (LJN452), SKU BA3602, can improve the design and interpretation of FXR-focused viability, proliferation, and intestinal barrier experiments. This scenario-based guide covers formulation, controls, assay compatibility, vendor selection, and evidence limits for biomedical research.

• ALC-0315: From Lipid Choice to Escape Strategy

  2026-09-30

  ALC-0315 is best evaluated as a controllable element of an LNP system, not as a standalone delivery solution. This translational guide connects its ionizable-lipid mechanism and practical handling requirements with emerging in vivo evidence that endosomal escape—not simply nanoparticle uptake—is a decisive bottleneck in therapeutic mRNA delivery.

• 3X FLAG Peptide: Evidence-Based Workflow Guide

  2026-09-30

  The 3X (DYKDDDDK) Peptide is a 23-residue hydrophilic FLAG epitope reagent for affinity purification, immunodetection, and structural workflows. Its defined solubility, storage, and metal-sensitive antibody-binding properties support reproducible assay planning when interpreted with appropriate controls.

• AMG 9810: TRPV1 Antagonist Workflow Guide

  2026-09-29

  Use AMG 9810 to separate TRPV1-dependent calcium entry and CGRP secretion from broader metabolic-stress effects in sensory neuron experiments. This practical guide covers solvent handling, concentration-response design, assay controls, and a cautious framework for connecting nociceptive signaling with the AMPK–SQSTM1 stress-response axis.

• ALC-0315: Practical LNP Formulation Guide

  2026-09-29

  ALC-0315 is an ionizable amino lipid used to develop lipid nanoparticles for nucleic acid drug delivery, including mRNA workflows. It is an organic-solvent-soluble, water-insoluble formulation component and should not be treated as a validated clinical composition or a standalone aqueous reagent.

• Cefoperazone Sodium Salt Assay Workflows

  2026-09-28

  Build reproducible MIC, MBC, β-lactamase-resistance, and bile-relevant experiments with Cefoperazone sodium salt. This guide combines a reference-style broth workflow with practical formulation, comparison, and troubleshooting strategies for gram-negative bacterial research.

• PPACK Dihydrochloride: Mechanism and Research Use

  2026-09-28

  PPACK Dihydrochloride is an irreversible inhibitor of human α-thrombin, with a product-reported inhibition constant (Ki) of 0.24 nM. D-Phenylalanyl-L-prolyl-L-arginine chloromethyl ketone supports experimental control of thrombin activity, but it should not be treated as a blocker of platelet P2 receptors.

• ALC-0315: LNP Formulation and Evidence

  2026-09-27

  ALC-0315 is an ionizable amino lipid used in lipid nanoparticle research for nucleic acid drug delivery. Its product specifications describe identity, purity, solubility, and storage, while a 2026 study shows that mixing conditions can change LNP properties and biological performance independently of lipid choice.

• ATRX Loss and RTK Inhibitor Sensitivity in Glioma

  2026-09-26

  ATRX loss may help explain why some high-grade glioma cells respond differently to receptor tyrosine kinase inhibitors. This article examines the study behind that hypothesis, outlines a rigorous validation strategy, and considers how to evaluate AZ 10417808 in a biomarker-aware research workflow without assuming an unverified target profile.

7655 records 1/511 page Next 12345 下5页 Last page